Abstract
Introduction: Urinary tract infections (UTI) represent the most frequent complications after transrectal focal ablation of prostate cancer. Single-shot antibiotic prophylaxis for prevention has not yet been described. Methods: In this cohort study of patients who received a high-intensity focused ultrasound (HIFU) ablation of prostate cancer within a registered prospective single-arm trial, we analyzed posttreatment UTI (≤30 days after HIFU) related to perioperative antibiotic management in an exploratory analysis: single-shot prophylaxis or targeted treatment for bacteriuria. Potential risk factors associated with UTI were evaluated by uni- and multivariate regression analyses. Results: In total, 55 patients were eligible for analysis. Of these, 76.4% received antibiotic single-shot prophylaxis. UTI occurred in 10.7% of all patients, 5.4% developed fever, 3.6% required hospitalization. An antibiotic single-shot prophylaxis helped to protect 90.5% of men from infectious complications. Estimated effects indicate that a longer posttreatment catheterization (OR 3.38, 95% CI 0.47–27.08) and larger ablation volume (OR 4.85, 95% CI 0.61–107.49) might be associated with the highest risk for UTI after treatment. Conclusion: Single-shot antibiotic prophylaxis compared to a targeted antibiotic treatment showed a similar effectivity to prevent patients from infectious complications and should be considered as an element of antibiotic stewardship. Further research on risk factors and antibiotic strategies is required.
References
1.
Guillaumier
S
, Peters
M
, Arya
M
, Afzal
N
, Charman
S
, Dudderidge
T
, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer
. Eur Urol
. 2018
Oct
;74
(4
):422
–9
.
[PubMed]
0302-28382.
von Hardenberg
J
, Westhoff
N
, Baumunk
D
, Hausmann
D
, Martini
T
, Marx
A
, et al. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. Urologic Oncology. 2018
;36(9):401 e1- e9.3.
Valerio
M
, Shah
TT
, Shah
P
, McCartan
N
, Emberton
M
, Arya
M
, et al. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study.
Urologic Oncology. 2017
;35(4):150 e1- e7. 4.
Valerio
M
, Dickinson
L
, Ali
A
, Ramachandran
N
, Donaldson
I
, Freeman
A
, et al. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT)
. Contemp Clin Trials
. 2014
Sep
;39
(1
):57
–65
.
[PubMed]
1551-71445.
Ahmed
HU
, Dickinson
L
, Charman
S
, Weir
S
, McCartan
N
, Hindley
RG
, et al. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study
. Eur Urol
. 2015
Dec
;68
(6
):927
–36
.
[PubMed]
0302-28386.
Murray
KS
, Ehdaie
B
, Musser
J
, Mashni
J
, Srimathveeravalli
G
, Durack
JC
, et al. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer
. J Urol
. 2016
Sep
;196
(3
):883
–90
.
[PubMed]
0022-53477.
Berge
V
, Dickinson
L
, McCartan
N
, Hindley
RG
, Diep
LM
, Emberton
M
, et al. Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer
. J Urol
. 2014
Jun
;191
(6
):1764
–9
.
[PubMed]
0022-53478.
American Society of Health-System
. Pharmacists (2013
) Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. [Cited 2019 Mar 16]. Available from: https://www.ashp.org/-/media/assets/policy-guidelines/docs/therapeutic-guidelines/therapeutic-guidelines-antimicrobial-prophylaxis-surgery.ashx9.
Guidelines
EA
. (2019
) Urological Infections.
Edn. presented at the EAU Annual Congress Barcelona 2019. [Cited 2019 Mar 16]. Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/10.
American Urological Association
. Best Practices Statements: Urological Procedures and Antimicrobial Prophylaxis. [Cited 2019 Nov 19]. Available from: https://www.auanet.org/guidelines/urologic-procedures-and-antimicrobial-prophylaxis-(2019)11.
Ahmed
HU
, Hindley
RG
, Dickinson
L
, Freeman
A
, Kirkham
AP
, Sahu
M
, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study
. Lancet Oncol
. 2012
Jun
;13
(6
):622
–32
.
[PubMed]
1470-204512.
Zowawi
HM
, Harris
PN
, Roberts
MJ
, Tambyah
PA
, Schembri
MA
, Pezzani
MD
, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology
. Nat Rev Urol
. 2015
Oct
;12
(10
):570
–84
.
[PubMed]
1759-481213.
Centers for Disease Control and Prevention
. (2017
) Procedure-associated Module 9: Surgical Site Infection (SSI) Event. [Cited 2019 Mar 16]. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf14.
European Centre for Disease Prevention and Control
. (2017
). Surveillance of surgical site infections and prevention indicators in European hospitals - HAI-Net SSI protocol, version 2.2. Stockholm: ECDC. [Cited 2019 Mar 16]. Available from: https://ecdc.europa.eu/sites/portal/files/documents/HAI-Net-SSI-protocol-v2.2.pdf. Accessed 16 March 2019.15.
Flores-Mireles
AL
, Walker
JN
, Caparon
M
, Hultgren
SJ
. Urinary tract infections: epidemiology, mechanisms of infection and treatment options
. Nat Rev Microbiol
. 2015
May
;13
(5
):269
–84
.
[PubMed]
1740-152616.
Feijoo
ER
, Sivaraman
A
, Barret
E
, Sanchez-Salas
R
, Galiano
M
, Rozet
F
, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes
. Eur Urol
. 2016
Feb
;69
(2
):214
–20
.
[PubMed]
0302-283817.
Ganzer
R
, Hadaschik
B
, Pahernik
S
, Koch
D
, Baumunk
D
, Kuru
T
, et al. Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound
. J Urol
. 2018
Apr
;199
(4
):983
–9
.
[PubMed]
0022-534718.
European Centre for Disease Prevention and Control
. (2018
) Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. Stockholm: ECD; [Cited 2019 Jun 15]. Available from: https://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-EARS-Net-2017.pdf19.
U.S. Food and Drug Administration
. (2016
) FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. [Cited 2019 Jun 15]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication fda-advises-restricting-fluoroquinolone-antibiotic-use-certain.20.
European Medicines Agency
. (2019
) Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics.
[Cited 2019 Jun 15]. Available from: https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf21.
Valerio
M
, Dickinson
L
, Ali
A
, Ramachadran
N
, Donaldson
I
, Mccartan
N
, et al. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer
. J Urol
. 2017
Mar
;197
(3 Pt 1
):647
–54
.
[PubMed]
0022-534722.
van den Bos
W
, Scheltema
MJ
, Siriwardana
AR
, Kalsbeek
AM
, Thompson
JE
, Ting
F
, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer
. BJU Int
. 2018
May
;121
(5
):716
–24
.
[PubMed]
1464-409623.
Barqawi
AB
, Stoimenova
D
, Krughoff
K
, Eid
K
, O’Donnell
C
, Phillips
JM
, et al. Targeted focal therapy for the management of organ confined prostate cancer
. J Urol
. 2014
Sep
;192
(3
):749
–53
.
[PubMed]
0022-534724.
Hale
Z
, Miyake
M
, Palacios
DA
, Rosser
CJ
. Focal cryosurgical ablation of the prostate: a single institute’s perspective
. BMC Urol
. 2013
Jan
;13
(1
):2
.
[PubMed]
1471-249025.
Lindner
U
, Weersink
RA
, Haider
MA
, Gertner
MR
, Davidson
SR
, Atri
M
, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial
. J Urol
. 2009
Oct
;182
(4
):1371
–7
.
[PubMed]
0022-534726.
Azzouzi
AR
, Emberton
M
; PCM301 study investigators
. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors’ reply
. Lancet Oncol
. 2017
Apr
;18
(4
):e188
.
[PubMed]
1470-204527.
Wagenlehner
FM
, Pilatz
A
, Bschleipfer
T
, Diemer
T
, Linn
T
, Meinhardt
A
, et al. Bacterial prostatitis
. World J Urol
. 2013
Aug
;31
(4
):711
–6
.
[PubMed]
0724-498328.
Wagenlehner
FM
, Grabe
M
, Naber
KG
, Bjerklund Johansen
TE
, Naber
CK
, Weidner
W
. [Antibiotic prophylaxis in urology]
. Urologe A
. 2011
Nov
;50
(11
):1469
–78
.
[PubMed]
0340-2592© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
